Form 4: Vaxcyte Director Jacks Lee Reports Acquisition of Common Stock and Stock Options

Director Jacks Lee reports acquisition of 1,550 shares of common stock and 7,250 stock options in Vaxcyte, Inc.

Summary

• On June 6, 2024, Jacks Lee, a director of Vaxcyte, Inc. (PCVX), reported the acquisition of 1,550 shares of common stock and 7,250 stock options.
• The 1,550 shares of common stock are related to restricted stock units (RSUs) that will fully vest on the earlier of June 6, 2025, or the day prior to the next annual meeting of stockholders, subject to continuous service.
• The stock options, with an exercise price of $72.51, also vest monthly and will fully vest on the earlier of June 6, 2025, or the day prior to the next annual meeting of stockholders, subject to continuous service, and expire on June 5, 2034.
• Following these transactions, Lee directly owns 1,550 shares of Vaxcyte common stock and 7,250 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a director suggests confidence, but it's a routine filing and doesn't provide strong directional information.

Positives

• The acquisition of stock and options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting schedules for the RSUs and stock options are contingent upon the director's continuous service, suggesting an incentive for continued involvement with the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future performance.

Stakeholder Impact

• The acquisition of shares by a director could positively influence shareholder sentiment.

Key Dates